Stanford Women's Cancer Center, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Institute of Cancer and Genomics, University of Birmingham, Birmingham, UK.
Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:59-78. doi: 10.1002/ijgo.12614.
The Gynecologic Oncology Committee of FIGO in 2014 revised the staging of ovarian cancer, incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of these malignancies are high-grade serous carcinomas (HGSC). Stage IC is now divided into three categories: IC1 (surgical spill); IC2 (capsule ruptured before surgery or tumor on ovarian or fallopian tube surface); and IC3 (malignant cells in the ascites or peritoneal washings). The updated staging includes a revision of Stage IIIC based on spread to the retroperitoneal lymph nodes alone without intraperitoneal dissemination. This category is now subdivided into IIIA1(i) (metastasis ≤10 mm in greatest dimension), and IIIA1(ii) (metastasis >10 mm in greatest dimension). Stage IIIA2 is now "microscopic extrapelvic peritoneal involvement with or without positive retroperitoneal lymph node" metastasis. This review summarizes the genetics, surgical management, chemotherapy, and targeted therapies for epithelial cancers, and the treatment of ovarian germ cell and stromal malignancies.
国际妇产科联盟(FIGO)妇科肿瘤学委员会于 2014 年修订了卵巢癌分期,将卵巢、输卵管和腹膜癌纳入同一系统。这些恶性肿瘤大多为高级别浆液性癌(HGSC)。目前,IC 期分为三类:IC1(手术溢洒);IC2(手术前囊破裂或卵巢或输卵管表面肿瘤);IC3(腹水或腹腔灌洗液中的恶性细胞)。更新的分期包括根据腹膜后淋巴结的单独扩散而不包括腹腔内扩散对 IIIC 期的修订。该类别现在进一步细分为 IIIA1(i)(最大直径≤10mm 的转移)和 IIIA1(ii)(最大直径>10mm 的转移)。IIIA2 期现为“伴有或不伴有腹膜后淋巴结阳性的微小盆腔外腹膜累及”转移。这篇综述总结了上皮性癌症的遗传学、手术管理、化疗和靶向治疗,以及卵巢生殖细胞和基质恶性肿瘤的治疗。